Dr Weber speaks with ecancertv at WCCS 2016 about checkpoint inhibitor therapy for treating melanoma.
He outlines ongoing and upcoming trials of PD-1/PD-L1 based immunotherapy, as well as immune modulation via OX40 and 41BB antibodies.
Dr Weber also highlights the therapeutic potential of combining immunotherapy with surgery, chemotherapy and most notably radiotherapy, in which radiation can be used to 'warm up' a 'cold' tumour, allowing the inflammation of radiation-damaged cells to recruit a greater immune response than immunotherapy alone.
ecancer's filming at WCCS 2016 has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.